Navigation Links
FDA Panel Cites Clot Risk From Contraceptive Patch

By Steven Reinberg
HealthDay Reporter

MONDAY, Dec. 12 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration on Friday said that the Ortho Evra birth control patch carries a higher risk of blood clots for women compared to older methods, but should not be taken off drug store shelves.

The panel, which based its decision on the results of a new review of the data, voted 19 to 5 that the benefits of Johnson & Johnson's Ortho Evra patch exceed its risks, which included a higher risk for blood clots lodging in the legs or lungs.

The panelists felt that the patch, first approved in 2001, remains a valuable option for those younger women who find it tough to stick to a daily regimen of the 'Pill,' the Associated Press reported.

"I have many teenagers and it's the only method they'll use -- for them it's the perfect method," Dr. Melissa Gilliam of the University of Chicago, told the AP.

The panel did vote 20 to 3 (with one abstention) that the patch's labeling requires updating to better inform women of the higher risk for clots.

Studies on risks associated with the patch have had conflicting results. The most recent study by the FDA found a 50 percent higher risk for clots for women on the Ortho Evra patch versus those on various forms of the 'Pill.' But FDA scientists stressed that the data was not conclusive, the AP said.

The news agency said that prescriptions for Ortho Evra have waned over the past five years, from 5 million in 2006 to around 1.3 million in 2010.

Friday's announcement followed on the heels of a decision by the same FDA-appointed panel on Thursday that several newer forms of oral contraceptives carry revised labels warning about an increased risk of potentially fatal blood clots.

The U.S. Food and Drug Administration advisers voted 21-5 in favor of the new labels for oral contraceptives such as Bayer's Yaz or Yasmin. Both contain a newer type of man-made progestin hormone called drospirenone, which could increase the chances of dangerous clots in the legs or lungs, compared to older forms of oral contraceptives. The newer contraceptives have been successfully marketed on the premise that they have fewer of the unwanted side effects of older hormone pills such as bloating, mood swings and acne.

Speaking ahead of the decision, Dr. Tara Narula, a cardiologist at Lenox Hill Hospital in New York City, said that the risk of clotting with the newer pills is "a low risk but the risk exists. The idea of the FDA looking at this and potentially increasing the warning has no downside. If anything, it increases awareness and that can only be a good thing."

Earlier Thursday, the panel members voted 15 to 11 that the newer contraceptives, which gained initial FDA approval in 2001, are a viable method of birth control, and that the benefits of preventing pregnancy outweigh the health risks.

While the FDA isn't obligated to follow the recommendations of its advisory panels, it usually does so.

More information

The U.S. Department of Health and Human Services has more about birth control at

SOURCES: Tara Narula, M.D., cardiologist, Lenox Hill Hospital, New York City; Associated Press

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
2. Expert Panel Pinpoints Environmental Culprits in Breast Cancer
3. FDA Panels to Weigh Safety of Newer Forms of the Pill
4. Panel of melanoma mutations opens door to new treatment possibilities
5. Many on Medical Guideline Panels Have Conflicts of Interest: Study
6. Panels Rejection of PSA Test Spurs Mixed Reaction From Experts
7. Osteoporosis Drugs Safety Subject of FDA Panel
8. U.S. Panel Recommends Free Coverage of Birth Control
9. FDA Panel Rejects Avastin for Breast Cancer
10. FDA Panels to Weigh Dosing Labels for Kids OTC Fever Relievers
11. FDA Panel Delays Action on Dyes Used in Foods
Post Your Comments:
Related Image:
FDA Panel Cites Clot Risk From Contraceptive Patch 
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology: